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INTRODUCTION:  The  World  Health  Organisation  deﬁnes  PEComa’s  as “a  mesenchymal  tumour  composed
of  histologically  and  immunohistochemically  distinctive  perivascular  cells”.1 These  ubiquitous  tumours
show  distinctive  perivascular  epithelioid  cell  differentiation  and  arise  most  commonly  at  visceral  and
abdominopelvic  sites.
PRESENTATION OF  CASE:  We  present  a case  of  a forty-two  year old  man  presenting  to accident  and
emergency  department  with  upper  gastro-intestinal  bleeding.  He  had  a palpable  epigatric  mass  on exam-
ination.  He  underwent  a CT Scan  Abdomen  which  displayed  a tumour  arising  from  the  gastric  wall.  Upper
GI  endoscopy  and  biopsy  was  carried  out  and  biopsied  were  taken  for  histological  analysis.  A primary  gas-
tric  PEComa  was diagnosed  and  the  patient  underwent  distal  polya  gastrectomy  and gastrojejunostomy.
This  is  believed  to be the  ﬁrst  reported  case  of  a Primary  malignant  gastric  PEComa.
DISCUSSION: Perivascular  epithelioid  carcinomas  were  ﬁrst  described  in  1943  as an  abnormal  myoblast
in  a  case  of renal  angiomyolipoma.  PEComas  display  a  strong  female  predominance  with  a typical  benign
course.  There  are  approximately  100  reported  cases  of PEComa  to  date,  with  55  of  which  were  malignant.
PEComa’s  may  be subdivided  into  benign,  uncertain  malignant  potential  and malignant.  Their  natural
history  can  be very  aggressive  leading  to  multiple  metastases  and  death  as  expected  with  a  high-grade
sarcoma.
CONCLUSION:  This  case  depicts  the aggressive  nature  of  malignant  gastric  PEComa’s.  The  majority  of
PEComa’s  are  benign  in  nature  and  have  a better  prognosis.  We  display  here  the  challenges  in ascertaining
a  deﬁnitive  diagnosis  and  management  of such  patients  due  to limited  clinical  studies.
gical © 2011 Sur
. Introduction
In 1991 Bonetti et al. suggested the term perivascular epithe-
ioid cell (PEC) to describe a characteristic cell type found in three
nusual mesenchymal lesions, lymphangiomyomatosis, clear cell
ugar tumour of the lung and angiomyolipoma of the liver and kid-
ey after noting the consistent morphological, immunophenotypic,
enetic and ultrastructural features.2 In 1996 Zamboni et al. subse-
uently employed the term PEComa to amalgamate this family of
esions conveying this perivascular epithelioid cell differentiation
fter noting the overlapping features of a benign clear cell sugar
umour of the lung and a PEComa of the pancreas, indicating the
ossibility that similar tumours could possibly arise in many if not
ll locations.3 Thus the term PEComa was introduced to include
ll similar lesions outside the lung. To date, there have been ﬁfty-
ve reported malignant cases, with only three presentations noted
ithin the gastro-intestinal tract, none of whom were gastric in
rigin.
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Immunohistochemically, nearly all PEComas show reactivity for
melanocytic (HMB-45 and/or Melan-A) and smooth muscle (actin
and/or desmin) markers.4 Also noted is a consistent theme within
PEComa’s during immunohistochemistry is the typical perivascu-
lar location. A genetic predispostition to renal angiomyolipoma has
been documented in individuals with an alteration to the tuberous
sclerosis complex located in the TSC1 and TSC2 genes on chro-
mosomes 9q and 16p. There is no known normal physiological
counterpart to the perivascular epithelioid cell however a num-
ber of hypotheses have been proposed including the derivation
from undifferentiated neural crest cells, a possible molecular alter-
ation from a myoblastic smooth muscle origin or evolution from a
pericytic origin.5
2. Case
We  present the case of a forty-two year old male who  pre-
sented with epigastric pain, melaena and weight loss. He had
a palpable epigastric mass which was ﬁxed, solid and irregular
Open access under CC BY-NC-ND license. on examination. He underwent an abdominal CT scan which dis-
closed a 10 cm × 7 cm mass obstructing the pylorus of the stomach,
associated with metastatic liver disease and retroperitoneal lym-
phadenopathy (Fig. 1). He proceeded to upper GI endoscopy which
-NC-ND license. 
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Fig. 1. CT abdomen displaying large mass obstructing the gastric pylorus.
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Fig. 3. Histological slide – melanoma marker – Melan A.
nancy should include tumour size greater than 70 mm,  a mitoticFig. 2. Large fungating mass in the pylorus on Upper GI endoscopy.
isplayed a large fungating mass occupying the distal 1/3 of his
tomach (Fig. 2).
Histology demonstrated a large cell malignant tumour which
as negative for all epithelial markers excluding carcinoma and
egative c-kit excluding GIST. The melanoma marker Melan-A
as positive. This prompted consideration of metastatic malignant
elanoma. Other Melan-A positive tumours were considered –
hese are few in number; primarily Adreno-cortical carcinoma and
onadal Serolti\Leydig cell tumours. However, both these tumours
onsistently express the immuno marker Inhibin, which was neg-
tive in this case thus virtually excluding these two tumours from
he differential.
Finally as the tumour expressed the muscle marker desmin, in
ddition to Melan-A, indicating myo-melanocytic differentiation
he possibility of a PEComa was considered (Figs. 3 and 4).
The patient underwent a distal polya gastrectomy and gastro-
ejunostomy due to recurrent symptomatic upper gastrointestinal
aemorrhage and obstruction (Fig. 5). Following gastrectomy, a
eﬁnitive histological diagnosis was made a malignant PEComa
f gastric origin was conﬁrmed, due to the presence of large
pithelioid and polygonal cells associated with positive immuno-
istochemical stains for desmin, Melan-A and EMA  (Fig. 6).
. DiscussionPEComa or perivascular epithelioid cell tumours are a family of
elated mesenchymal neoplasms composed of histologically and
mmunohistochemically distinctive perivascular epithelioid cellsFig. 4. Muscle marker – desmin positive.
that include angiomyolipoma, lymphangiomyomatosis, clear cell
sugar tumours of the lung and a group of rare visceral, retroperi-
toneal and abdominopelvic tumours.1 They were ﬁrst described in
1943 as an abnormal myoblast in a case of renal angiomyolipoma.
PEComa’s display a strong female predominance with a typical
benign course. Recurrent chromosomal alterations involving the
tuberous sclerosis complex have been demonstrated in the perivas-
cular epithelioid cell. There are approximately 100 reported cases
of PEComa, with 55 of whom were malignant.
PEComa’s may  be subdivided into benign, uncertain malignant
potential and malignant. Guidelines regarding the classiﬁcation
criteria for malignant cases of PEComa’s have not yet been interna-
tionally agreed upon due to the rarity of cases, however it is agreed
that they pursue an consistently aggressive clinical course. How-
ever, after review and follow up of PEComa’s arising at visceral and
somative sites Folpe et al. hypothesised that the criteria for malig-index of greater than 1 per 50 high power ﬁeld, inﬁltrative growth
patterns and marked hypercellularity, pleomorphism, necrosis and
nuclear atypia.6
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Fig. 5. Gross intra-operative specimen – tumour involving distal greater curvature
of the stomach.
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cFig. 6. Final gross histological specimen post resection.
Their natural history can be very aggressive leading to multiple
etastases and death as expected with a high-grade sarcoma. It is
stimated that the mean survival time of patients with malignant
EComas affecting the terminal Ileum & Caecum is 28 months and
esentery and Colon, 27 months and 38 months, respectively. A
ecent case by Slevaggi et al. reported 25 day mortality in a 42 year
ld male with a malignant PEComa which was hepatic in origin.7
his has reﬂected our own experience in the case outlined here with
ur patient not surviving greater than 3 months since diagnosis.
The sparity of PEComa diagnosis and restricted clinical follow
p time in aggressive malignant cases is limited throughout the
iterature. Due to this, issues regarding the origin of this unusual
ell differentiation, clinical behaviour and patterns of disease pro-
ression remains elusive. Longer clinical follow up of known cases
nd the evaluation of any additional patients is required. A recent
mall case series and a separate case report have shown improved
8
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ermits unrestricted non commercial use, distribution, and reproduct
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clinical and radiological responses to the mTOR inhibitors,
sirolimus and temsirolimus.8 This may well represent a promis-
ing targeted therapeutic approach. Therefore a diagnosis of PEComa
introduces a number of dilemmas with regard to optimum manage-
ment and treatment of the primary and any subsequent metastatic
disease. The need for implementation of guidelines for favourable
screening programmes and the role of adjuvant therapies for local
and metastatic disease bulk are required.
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